Literature DB >> 17914186

Reversible unilateral nigrostriatal pathway inhibition induced through expression of adenovirus-mediated clostridial light chain gene in the substantia nigra.

Jun Yang1, Qingshan Teng, Mary E Garrity-Moses, Shearwood McClelland, Thais Federici, Erin Carlton, Jonathon Riley, Nicholas M Boulis.   

Abstract

Clostridial light chain (LC) inhibits synaptic transmission by digesting a vesicle-docking protein, synaptobrevin, without killing neurons. We here report the feasibility of creating a rat hemiparkinsonism model through LC gene expression in the substantia nigra (SN), inhibiting nigrostriatal transmission. 40 adult Sprague Dawley rats were divided into four groups for SN injections of PBS, 6-hydroxydopamine (6-OHDA), or adenoviral vectors for the expression of LC (AdLC), or GFP (AdGFP). Amphetamine and apomorphine induced rotations were assessed before and after SN injection, revealing significant rotational alterations at 8 or 10 days after injection in both AdLC and 6-OHDA but not PBS and AdGFP groups. Induced rotation recovered by one month in AdLC rats but persisted in 6-OHDA rats. Histological analysis of the SN revealed LC and GFP expression with corresponding synaptobrevin depletion in the LC, but not the GFP groups. Tyrosine hydroxylase (TH) and dopamine transporter (DAT) immunohistochemistry (IHC) showed markedly decreased staining in ipsilateral SN and striatum in 6-OHDA but not AdLC or AdGFP rats. Similarly, compared with contralateral, ipsilateral striatal dopamine level only decreased in 6-OHDA but not AdLC, AdGFP, or PBS treated rats. Thus, LC expression induces nigral synaptobrevin depletion with resulting inhibition of nigrostriatal synaptic transmission. Unlike 6-OHDA, LC expression inhibits synaptic activity without killing neurons. This approach, therefore, represents a potentially reversible means of nigrostriatal pathway inhibition as a model for Parkinson's disease. Such a model might facilitate transient and controlled nigral inhibition for studying striatal recovery, dopaminergic re-innervation, and normalization of striatal receptors following the recovery of nigrostriatal transmission.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914186     DOI: 10.1007/s12017-007-8003-0

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  35 in total

1.  Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances.

Authors:  U Baron; H Bujard
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

2.  Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.

Authors:  Kizhakke M Sindhu; Karuppagounder S Saravanan; Kochupurackal P Mohanakumar
Journal:  Brain Res       Date:  2005-07-27       Impact factor: 3.252

3.  Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.

Authors:  Ruxandra Iancu; Paul Mohapel; Patrik Brundin; Gesine Paul
Journal:  Behav Brain Res       Date:  2005-07-01       Impact factor: 3.332

4.  Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion.

Authors:  C K Meshul; N Emre; C M Nakamura; C Allen; M K Donohue; J F Buckman
Journal:  Neuroscience       Date:  1999-01       Impact factor: 3.590

Review 5.  Adeno-associated virus vectors: activity and applications in the CNS.

Authors:  A L Peel; R L Klein
Journal:  J Neurosci Methods       Date:  2000-06-01       Impact factor: 2.390

6.  Comparison of embryonic stem cell-derived dopamine neuron grafts and fetal ventral mesencephalic tissue grafts: morphology and function.

Authors:  David M Yurek; Anita Fletcher-Turner
Journal:  Cell Transplant       Date:  2004       Impact factor: 4.064

Review 7.  Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release.

Authors:  G Schiavo; O Rossetto; C Montecucco
Journal:  Semin Cell Biol       Date:  1994-08

8.  Reversible suppression of glutamatergic neurotransmission of cerebellar granule cells in vivo by genetically manipulated expression of tetanus neurotoxin light chain.

Authors:  Mutsuya Yamamoto; Norio Wada; Yasuji Kitabatake; Dai Watanabe; Masayuki Anzai; Minesuke Yokoyama; Yutaka Teranishi; Shigetada Nakanishi
Journal:  J Neurosci       Date:  2003-07-30       Impact factor: 6.167

9.  A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.

Authors:  C Warren Olanow; Christopher G Goetz; Jeffrey H Kordower; A Jon Stoessl; Vesna Sossi; Mitchell F Brin; Kathleen M Shannon; G Michael Nauert; Daniel P Perl; James Godbold; Thomas B Freeman
Journal:  Ann Neurol       Date:  2003-09       Impact factor: 10.422

Review 10.  Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.

Authors:  Ronald Deumens; Arjan Blokland; Jos Prickaerts
Journal:  Exp Neurol       Date:  2002-06       Impact factor: 5.330

View more
  3 in total

1.  Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.

Authors:  Sara E Gombash; Jack W Lipton; Timothy J Collier; Lalitha Madhavan; Kathy Steece-Collier; Allyson Cole-Strauss; Brian T Terpstra; Anne L Spieles-Engemann; Brian F Daley; Susan L Wohlgenant; Valerie B Thompson; Fredric P Manfredsson; Ronald J Mandel; Caryl E Sortwell
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Neuronal transgene expression in dominant-negative SNARE mice.

Authors:  Takumi Fujita; Michael J Chen; Baoman Li; Nathan A Smith; Weiguo Peng; Wei Sun; Michael J Toner; Benjamin T Kress; Linhui Wang; Abdellatif Benraiss; Takahiro Takano; Su Wang; Maiken Nedergaard
Journal:  J Neurosci       Date:  2014-12-10       Impact factor: 6.167

3.  DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats.

Authors:  Puneet K Sharma; Lisa Wells; Gaia Rizzo; Joanna L Elson; Jan Passchier; Eugenii A Rabiner; Roger N Gunn; David T Dexter; Ilse S Pienaar
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.